A US pharmaceutical company is defending its decision to boost the price of one of its medications used by AIDS patients by over 5000%. CEO Martin Shkreli says the money they make from the boosted price of the medication will go into research for new treatments. One dose of the drug has gone from $13.50 to $750 – and one pill costs only $1.00 to produce. When questioned by the media, Shkreli called one reporter a ‘moron’. While the practice is not out of line with the industry, Shkreli has been getting tonnes of flack online – even presidential candidate Hilary Clinton weighing in on the situation, pledging to take action against firms hiking prices for specialty drugs. Is this the cost of doing business or unethical profiteering?